Serum Glucagon like peptide 1 Level and Peripheral Vascular Disease in Patients with Type 2 Diabetes

Abstract

Abstract Background Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. Incretins are hormones produced by the intestinal mucosa in response to oral intake of nutrients that enhance glucose-stimulated insulin secretion and lower blood glucose levels. GLP-1 is of particular interest for its glucoselowering effects, as well as its ability to slow gastric emptying and suppress secretion of glucagon. Objective To assess the level of glucagon like peptide-1 in type 2 diabetic patients with peripheral vascular disease. Patients and Methods Our study was conducted in the period from 1st of January to 1st of June 2017. Our subjects were collected from the diabetes clinics of Ain Shams university Hospitals. The study included eighty (80) patients divided into 40 type 2 diabetic patients without peripheral vascular disease (Group 1) and 40 type 2 diabetic patients with peripheral vascular disease (Group 2). Results Diabetic patients with peripheral vascular disease show statistically significant higher HbA1c levels than diabetic patients without peripheral vascular disease with P-value 0.005 (P-value <0.05). GLP 1 was highly significantly positively correlated with APSV with P-value< 0.001. GLP 1 correlated negatively with BMI, FBS, 2h PPBS and HbA1C; with statistically significant difference; P-value (0.031, 0.015, 0.033 and 0.010 respectively) but was not significantly negatively correlated with age, SBP and DBP; P-value (0.232, 0.654 and 0.335 respectively). Conclusion GLP-1 levels are lower in diabetic patients with peripheral vascular disease than diabetic patients without peripheral vascular disease. GLP-1 levels showed significantly lower levels with increasing degree of obesity, FBS, PPBS and HbA1c.